10-Q: Charlotte's Web Q3 Loss Narrows Amid Strategic Shifts

Charlotte's Web Holdings, Inc. reported a narrower operating loss in Q3 2025, driven by significant cost reductions and strategic business model adjustments, despite a decline in revenue.

Summary

• Net loss for Q3 2025 was $(5.8) million, comparable to $(5.8) million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, improved to $(18.3) million from $(26.5) million in the prior year.
• Revenue for Q3 2025 decreased by 8.6% to $11.5 million, primarily due to a 48% reduction in B2B revenues as the company shifts to a distributor model.
• Selling, General, and Administrative (SG&A) expenses decreased by 23.3% in Q3 2025 to $9.7 million, largely due to the termination of the MLB Promotional Rights Agreement and other cost-cutting measures.
• Gross profit for Q3 2025 fell by 32.9% to $4.5 million, with gross margin compressing to 38.9% due to a one-time B2B retail chargeback reserve and temporary in-house manufacturing inefficiencies.
• Cash and cash equivalents decreased from $22.6 million at December 31, 2024, to $9.8 million at September 30, 2025.
• The company's investment in DeFloria LLC, a botanical drug development entity, saw a loss of $1.5 million for the nine months ended September 30, 2025, and the FDA cleared DeFloria for Phase 2 clinical trials for AJA001 Oral Solution for ASD.

Sentiment

Score: 4

Explanation: While the company has made significant strides in cost reduction and strategic diversification, the continued decline in revenue, substantial cash burn, and gross margin compression in the quarter indicate ongoing financial challenges. The positive developments in R&D and the MLB agreement termination are offset by the immediate financial pressures and the negative swing in financial instrument valuations.

Positives

• Operating loss significantly improved for both the three months (from $(6.0) million to $(5.3) million) and nine months (from $(26.5) million to $(14.7) million) ended September 30, 2025.
• Selling, General, and Administrative (SG&A) expenses decreased substantially by 23.3% in Q3 2025 and 26.5% for the nine months, driven by the termination of the MLB Promotional Rights Agreement and other cost-cutting initiatives.
• Termination of the MLB Promotional Rights Agreement resulted in a $2.3 million gain and waived $18 million in future rights fees.
• Net cash used in operating activities improved to $(12.2) million for the nine months ended September 30, 2025, from $(19.5) million in the prior year.
• FDA cleared DeFloria LLC, a collaboration entity, to proceed with Phase 2 clinical trials for AJA001 Oral Solution, a botanical pharmaceutical candidate for autism spectrum disorder (ASD).
• Launch of Charlotte's Web Stay Asleep Cannabinol ("CBN") gummies, expanding product offerings beyond CBD into broader botanical-based wellness solutions.

Negatives

• Total revenue decreased by 8.6% to $11.5 million for Q3 2025 and by 1.2% to $36.6 million for the nine months ended September 30, 2025.
• Gross profit declined by 32.9% to $4.5 million in Q3 2025, with gross margin compressing to 38.9% from 53.0% in the prior year, partly due to a one-time $0.5 million B2B retail chargeback reserve and temporary scaling inefficiencies from in-house manufacturing.
• Cash and cash equivalents significantly decreased from $22.6 million at December 31, 2024, to $9.8 million at September 30, 2025.
• Total shareholders' equity decreased from $27.1 million at December 31, 2024, to $9.2 million at September 30, 2025.
• A significant negative swing in the change in fair value of financial instruments, resulting in a loss of $(1.2) million for Q3 2025 and $(2.9) million for the nine months, compared to gains in the prior year periods.
• The company determined it is highly unlikely to exercise the Stanley Brothers USA Holdings Purchase Option, resulting in a $52,000 loss and nil value for the asset.

Risks

• Regulatory changes in various states may impact the ability to sell certain products as currently formulated or packaged, including new THC/CBD limits, age verification, testing, labeling, and packaging requirements.
• The company's ability to fund long-term operations depends on future operating performance, revenue growth, and expense management, which are subject to general economic conditions, industry regulatory changes, and other external factors.
• Raising additional capital through equity or debt securities is dependent on capital market conditions, investor sentiment, and the intended use of proceeds.
• Fair value determinations for financial instruments (DeFloria investment, debt interest rate conversion feature, debt conversion option) involve a high degree of subjectivity and judgment using unobservable inputs, leading to estimation uncertainty.
• Potential for legal proceedings, claims, and regulatory issues, though management currently believes no material adverse effect is expected.

Future Outlook

Management expects a reduction in overall selling, general, and administrative expenses for the remainder of 2025 due to actions taken in late 2024 and additional projected reductions. The company is focused on reducing negative cash flows from operations in the near to mid-term and believes existing cash and short-term investments will provide sufficient liquidity for the next 12 months. Long-term funding depends on future operating performance, revenue growth, and expense management, as well as potential capital raises.

Management Comments

• "Our objective when managing our liquidity and capital resources is to provide sufficient short and long-term liquidity to fund net operating losses and capital expenditures while executing strategic growth plans. In the near to mid-term, we are focused on reducing negative cash flows from operations."
• "We believe that our existing cash and cash equivalents, and short-term investments will provide sufficient liquidity to fund operations and planned capital expenditures for the next 12 months."
• "We expect a reduction in overall selling, general, and administrative expenses in the remainder of 2025 as a result of several actions taken in the second half of 2024, as well as additional reductions projected in the second half of 2025."
• "We continue to assess the business and financial impacts of the new regulations, including steps that can be taken to address the new product formulation, and labeling requirements, as well as costs and potential revenue impacts and anticipated timing for such impacts to the Company in these states."

Industry Context

Charlotte's Web operates in the evolving hemp-derived CBD and botanical wellness industry, which is characterized by ongoing regulatory changes at the state level and increasing demand for diverse natural health solutions. The company's expansion into CBN gummies and botanical drug development through DeFloria aligns with a broader industry trend of diversifying product portfolios beyond traditional CBD and pursuing pharmaceutical applications for cannabinoids. The FDA's clearance for DeFloria's Phase 2 clinical trial positions Charlotte's Web at the forefront of scientific validation in the botanical drug space, potentially differentiating it from competitors focused solely on consumer products. However, the industry also faces challenges from inconsistent state regulations and the need for robust scientific evidence to support product claims.

Legal Proceedings

• The company is a party to various lawsuits, claims, and other legal proceedings that arise in the ordinary course of business.
• Management believes there is no litigation pending that could have a material adverse effect on the company's financial position, results of operations, or cash flows as of September 30, 2025.
• The company is not a party to any material pending legal proceedings, other than ordinary routine litigation incidental to the business.

Related Party Transactions

• A secured promissory note of $1,000,000 was loaned to one of the Stanley Brothers in November 2020, with the maturity date extended to November 13, 2029. The note has been fully reserved for as of December 31, 2024.
• The SBH Purchase Option with Stanley Brothers USA, purchased for $8,000,000, was determined to be highly unlikely to be exercised and now has a nil financial asset value as of September 30, 2025.
• DeFloria LLC, jointly formed with AJNA BioSciences PBC and a subsidiary of British American Tobacco PLC, involves Charlotte's Web holding 4,000,000 common units, supplying raw material at cost, and providing services.
• An 8% interest-bearing note receivable with DeFloria for the sale of lab equipment had a remaining balance of $28,000 as of September 30, 2025.
• Revenue and cost of goods sold of $641,000 for the nine months ended September 30, 2025, related to the supply agreement with DeFloria.
• Revenue and cost of goods sold of $225,000 for the nine months ended September 30, 2025, related to the master services agreement with DeFloria.
• An accounts receivable balance due from DeFloria of $1,134,000 as of September 30, 2025.
• A promissory note of $750,000 was loaned to DeFloria on July 15, 2025, with a balance of $575,000 as of September 30, 2025, due upon the later of December 31, 2026, or DeFloria raising $10 million in financing.
• A consulting agreement with Jared Stanley (former executive, current Board member) for a bi-weekly fee of $6,000.

Stakeholder Impact

• Shareholders: Experience continued net losses and a significant decrease in total shareholders' equity, but benefit from reduced operating losses and strategic moves like the MLB agreement termination. Potential for long-term value from DeFloria's clinical trials.
• Employees: Impacted by cost-cutting measures, including workforce adjustments, but also benefit from share-based compensation plans.
• Customers: Benefit from new product offerings like CBN gummies and the company's commitment to science-backed wellness solutions.
• Creditors: The convertible debenture holder (BAT Group) has a significant stake and conversion options, with interest accruing. The promissory note to DeFloria indicates ongoing financial support to a related entity.
• Suppliers: The company sources hemp through contract farming operations and supplies raw materials to DeFloria, indicating ongoing relationships.

Next Steps

• Continue assessing business and financial impacts of new state regulations on product formulation, labeling, and potential revenue.
• Further align operating expenses with current revenue levels through additional cost-cutting measures in the remainder of 2025.
• DeFloria LLC to proceed with planned FDA Phase 2 clinical trial for AJA001 Oral Solution.
• Continue investing in R&D efforts to identify new product opportunities and expand product lines beyond hemp-based products.
• Evaluate the effect of adopting new FASB ASUs (2025-06, 2025-05, 2024-04, 2024-03, 2023-09) in future periods.

Key Dates

Recommendation

Charlotte's Web is in a transitional phase, marked by significant cost-cutting and strategic shifts to improve operational efficiency and diversify its product portfolio. While the company successfully reduced its operating loss and SG&A expenses, revenue continues to decline, and cash burn remains a concern, leading to a substantial reduction in cash and shareholders' equity. The FDA clearance for DeFloria's Phase 2 clinical trial represents a long-term growth opportunity in the pharmaceutical cannabinoid space, but its impact on current financials is limited. The stock is a 'hold' for investors willing to tolerate near-term volatility and continued losses, betting on the successful execution of strategic initiatives, further cost efficiencies, and the long-term potential of its R&D and product diversification efforts in a challenging regulatory environment.

Keywords

Charlotte's Web, CWEB, CBD, Hemp, Botanical Wellness, Cannabinoids, CBN, FDA Clinical Trials, DeFloria, SEC Filing, 10-Q, Financial Results, Cost Reduction, Strategic Shift, Q3 2025, Cannabis Industry, Consumer Health